Ligand Pharmaceuticals (LGND) Net Income towards Common Stockholders Growth (5y) (2015 - 2026)
Ligand Pharmaceuticals (LGND) Net Income towards Common Stockholders Growth (5y) (2015 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
| 10 |
Ligand Pharmaceuticals |
5.47 Bn |
4.69 Bn |
48.45 Mn |
| Date | Value |
|---|
| Mar 31, 2026 |
-23.42% |
| Dec 31, 2025 |
20.55% |
| Sep 30, 2025 |
81.14% |
| Jun 30, 2025 |
-26.16% |
| Mar 31, 2025 |
-11.96% |
| Dec 31, 2024 |
-33.38% |
| Mar 31, 2023 |
-15.29% |
| Mar 31, 2021 |
-52.97% |
| Dec 31, 2020 |
22.63% |
| Sep 30, 2020 |
-15.25% |
| Mar 31, 2020 |
-60.84% |
| Dec 31, 2019 |
-42.40% |
| Sep 30, 2019 |
-63.26% |
| Jun 30, 2019 |
-72.56% |
| Jun 30, 2018 |
98.12% |
| Mar 31, 2018 |
198.52% |
| Mar 31, 2016 |
183.38% |
| Dec 31, 2015 |
24.10% |
| Sep 30, 2015 |
598.24% |
